Successful use of defibrotide to treat allogeneic hematopoietic stem cell transplantation associated thrombotic microangiopathy in pediatric patients: report from Chinese single center-Reference-Cited by-同舟云学术

Successful use of defibrotide to treat allogeneic hematopoietic stem cell transplantation associated thrombotic microangiopathy in pediatric patients: report from Chinese single center

Published:2024-07-23 Issue: Volume: Page:
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Wang Jiayu,Luo Yanhui,Jia Chenguang,Yang Jun,Wang Bin,Zheng Jie,Jing Yuanfang,Chen Wei,Yang Wei,Zhu Guanghua^ORCID,Qin Maoquan^ORCID,Li Sidan^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41409-024-02368-2.pdf

Reference12 articles.

1. García-Martín P, Alarcón-Payer C, López-Fernández E, Moratalla L, Romero A, Sainz J, et al. Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease. Ann Pharmacother. 2015;49:986–94.

2. Pagliuca S, Michonneau D, Sicre de Fontbrune F, Sutra Del Galy A, Xhaard A, Robin M, et al. Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions. Blood Adv. 2019;3:2424–35.

3. Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM, et al. A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev. 2015;29:191–204.

4. Elfeky R, Lucchini G, Lum SH, Ottaviano G, Builes N, Nademi Z, et al. New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT. Blood Adv. 2020;4:2418–29.

5. Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, et al. Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. Br J Haematol. 2020;189:1171–81.